A 6-month, double-blind, randomized, placebo-controlled, Cognition Maintenance Study (CMS) in patients with Alzheimer's disease who complete at least one year of open-label treatment with simufilam
Latest Information Update: 15 May 2023
At a glance
- Drugs Simufilam (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cassava Sciences
- 11 May 2023 According to a Cassava Sciences media release, over 125 patients completed dosing.
- 28 Feb 2023 According to a Cassava Sciences media release, company expects to complete dosing of this study in Q2 2023.
- 03 Aug 2022 According to a Cassava Sciences media release, the company expects to announce clinical results of the study approximately third-quarter 2023.